1-2 of 2
Vincenzo Callea, M.D.
Close
Sort by
Journal Articles

Clinical Outcomes According to Genomic Abnormalities in 566 Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.

Michele Cavo, M.D., Sara Bringhen, M.D., Nicoletta Testoni, B.S., Paola OmedeĢ€, B.S., Giulia Marzocchi, B.S., Marina Ruggeri, B.S., Sandra Durante, B.S., Francesco Di Raimondo, M.D., Davide Rossi, M.D., Ausilia Gorgone, M.D., Francesca Patriarca, M.D., Maria Teresa Petrucci, M.D., Silvia Buttignol, M.D., Anna Levi, M.D., Massimo Offidani, M.D., Chiara Nozzoli, M.D., Roberto Ria, M.D., Barbara Olivero, M.D., Monica Galli, M.D., Vittorio Montefusco, M.D., Vincenzo Callea, M.D., Antonietta Falcone, M.D., Antonio De Vivo, M.D., Mario Boccadoro, MD, Carolina Terragna, B.S., Antonio Palumbo, M.D.
Journal: Blood
Blood (2009) 114 (22): 1868.
https://doi.org/10.1182/blood.V114.22.1868.1868
Published: 2009
Journal Articles

Bortezomib (VelcadeĀ®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM).

Michele Cavo, MD, Francesca Patriarca, M.D., Paola Tacchetti, M.D., Monica Galli, M.D., Giulia Perrone, M.D., Maria Teresa Petrucci, M.D., Annamaria Brioli, M.D., Sara Bringhen, M.D., Lucia Pantani, M.D., Patrizia Tosi, M.D., Claudia Crippa, M.D., Elena Zamagni, M.D., Francesco Di Raimondo, M.D., Franco Narni, M.D., Claudia Cellini, M.D., Michela Ceccolini, M.D., Norbert Pescosta, M.D., Maria Cecilia Goldaniga, M.D., Vittorio Montefusco, M.D., Vincenzo Callea, M.D., Valerio De Stefano, M.D., Tommaso Caravita, M.D., Mario Boccadoro, M.D., Michele Baccarani, M.D.
Journal: Blood
Blood (2007) 110 (11): 73.
https://doi.org/10.1182/blood.V110.11.73.73
Published: 2007